Hydroxyprogesterone Caproate Injection as a Technique to Reduce Preterm Birth in High-Risk Pregnancies (Medicaid Expansion) (ARCHIVED)

Policy ID: ME-I-56-027-05

Section: Injections

Effective Date: January 01, 2022

Revised Date: January 13, 2025

Revision Effective Date: February 28, 2025

Last Reviewed: January 14, 2025

Applies To: Medicaid Expansion Only

This policy has been Archived effective February 28, 2025. Click the Archive tab above for more information.

Policy ID: ME-I-56-027-05

Section: Injections

Effective Date: January 01, 2022

Revised Date: January 13, 2025

Revision Effective Date: February 28, 2025

Last Reviewed: January 14, 2025

Archived Date: February 28, 2025

Applies To: Medicaid Expansion Only

Description

Preterm labor and delivery is a major cause of neonatal morbidity and mortality. Women who have had a spontaneous preterm delivery are at increased risk for preterm delivery in subsequent pregnancies.

Criteria

Coverage is subject to the specific terms of the member's benefit plan.

Makena (hydroxyprogesterone caproate) is considered experimental/investigational and therefore non-covered as there is a lack of conclusive evidence confirming clinical efficacy.

Procedure Code

J1726

NOTE: J1729 may be considered medically necessary for FDA-approved or compendia supported indications.

NOTE: All products under J1729 became inactive as of November 29, 2023.

Diagnosis Codes

Covered Diagnosis Codes for Procedure Code J1729

C54.0

C54.1

C54.2

C54.3

C54.8

C54.9

N20.1

N20.2

N20.9

N91.0

N91.1

N91.2

N93.8

Professional Statements and Societal Positions Guidelines

Not Applicable

ND Committee Review

Internal Medical Policy Committee 11-23-2021 - Effective January 1, 2022

Adopted Medicaid Expansion specific policy

Internal Medical Policy Committee 11-29-2022 - Effective January 1, 2023

Updated initial criteria, and
Updated experimental/investigational statement

Internal Medical Policy Committee 5-23-2023 - Effective April 7, 2023

Updated policy to make Makena (hydroxyprogesterone caproate) always experimental/investigational due to the FDA withdrawal of approval of Makena which occurred on April 6, 2023.
Removed J1729 from the criteria
Added Note concerning J1729

Internal Medical Policy Committee 1-16-2024 - Effective March 01, 2024

Added note: All products under J1729 became inactive as of November 29, 2023
Added diagnosis codes for J1729 for any supply that is being depleted

Internal Medical Policy Committee 10-14-2025 Effective February 28, 2025

Archived policy

Links

INSERT REFERENCE LINK

Disclaimer

Current medical policy is to be used in determining a Member's contract benefits on the date that services are rendered. Contract language, including definitions and specific inclusions/exclusions, as well as state and federal law, must be considered in determining eligibility for coverage. Members must consult their applicable benefit plans or contact a Member Services representative for specific coverage information. Likewise, medical policy, which addresses the issue(s) in any specific case, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and the Company reserves the right to review and update medical policy periodically.

Our Partners in Health:
Members
Employers
Producers

Fargo (Headquarters)
4510 13th Ave. S.
Fargo, N.D., 58121

Medical Policies Quick Search